English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Objective: To assess the effects of Metformin, Dichloroacetate  (DCA) and their combination on cell viability in oral squamous  cell carcinoma, UPCI-SCC-131 cell line. Methods: UPCI-SCC-131 cells were plated in 96 E-plate (1x104  cells/well) and were treated with Metformin (1-16mM) and/or  DCA (15-120mM) for 24-48-72h. xCELLigence SP system was used  to monitor real time cell viability. In addition, drug combination  index was analyzed with CompuSyn software according to  Chou-Talalay method. Results: Half-maximal inhibitory concentrations (IC50) of Metformin  and DCA were found to be 3mM and 23mM, respectively,  for 72 hours. CI values (0.76-0.80) in all combination groups below  1 indicated that Metformin/DCA combination had a moderate  synergistic effect on cell viability in UPCI-SCC-131 cells. Discussion: Metformin/DCA combination synergistically decreased  the cell viability of UPCI-SCC-131 cells. Therefore, a combined  application of Metformin and DCA may be considered as  a candidate therapy for the “drug repositioning” of the treatment  of oral cavity cancer.

METFORMIN AND DICHOLOROACETATE COMBINATION EXERT A SYNERGISTIC EFFECT ON CELL VIABILITY OF ORAL SQUAMOUS CELL CARCINOMA